The latest data point for RXRX's revenue in Q4'25 shows a significant increase to $35.54M USD, marking a strong recovery and the highest quarterly figure in the observed period from Q1'23 to Q4'25. Over the timeframe from Q1'23 to Q4'25, revenue exhibited volatility with an initial decline from $12.13M in Q1'23 to a low of $10.53M in Q3'23, followed by moderate growth to $14.42M in Q2'24 and a sharp spike to $26.08M in Q3'24, before dipping to $4.55M in Q4'24. Subsequent quarters saw fluctuations, including a drop to $5.18M in Q3'25, but year-over-year growth turned highly positive at 681.74% in Q4'25, indicating robust expansion driven by potential new revenue streams or operational improvements, though the overall trend remains inconsistent with periods of contraction offsetting gains.